Home Fear & Greed Pools Wallets Dictionary Advertise Facebook Twitter Telegram Reddit Youtube
Market Cap:
24h Vol:
Cryptocurrencies: 13285
Markets: 101139
CoinInsight360.com logo CoinInsight360.com logo
ENG
EST
RUS
TUR
DEU
CHI
KOR
ITA
USD
USD
AED
AFN
ALL
AMD
ANG
AOA
ARS
AUD
AWG
AZN
BAM
BBD
BDT
BGN
BHD
BIF
BMD
BND
BOB
BRL
BTN
BWP
BYN
BZD
CAD
CDF
CHF
CLF
CLP
CNH
CNY
COP
CRC
CUC
CUP
CVE
CZK
DJF
DKK
DOP
DZD
EGP
ERN
ETB
EUR
FJD
FKP
GBP
GEL
GHS
GIP
GMD
GNF
GTQ
GYD
HKD
HNL
HRK
HTG
HUF
IDR
ILS
IMP
INR
ISK
JMD
JOD
JPY
KES
KGS
KHR
KMF
KPW
KRW
KWD
KYD
KZT
LAK
LBP
LKR
LRD
LSL
LYD
MAD
MDL
MGA
MKD
MMK
MNT
MOP
MRU
MUR
MVR
MWK
MXN
MYR
MZN
NAD
NGN
NIO
NOK
NPR
NZD
OMR
PAB
PEN
PGK
PHP
PKR
PLN
PYG
QAR
RON
RSD
RUB
RWF
SAR
SBD
SCR
SDG
SEK
SGD
SHP
SLL
SRD
SSP
STD
STN
SVC
SYP
SZL
THB
TJS
TMT
TND
TOP
TRY
TTD
TWD
TZS
UAH
UGX
UYU
UZS
VES
VND
VUV
WST
ZAR
ZMW
ZWL
America's Social Casino

Market Cap
24h Vol
13285
Cryptocurrencies
64.41%
Bitcoin Share
coinpedia 2025-05-07 08:57:52

Coinbase CEO Brian Armstrong Bags $130M for Longevity Startup NewLimit

Coinbase CEO Brian Armstrong Bags $130M for Longevity Startup NewLimit

The post Coinbase CEO Brian Armstrong Bags $130M for Longevity Startup NewLimit appeared first on Coinpedia Fintech News While most crypto CEOs are busy navigating market volatility, Brian Armstrong is playing a far bigger game – taking on human aging and Washington regulations at the same time. Not exactly your typical founder story, right? One moment he’s rallying for stablecoin legislation on Capitol Hill, the next he’s funding research to literally reverse the aging process. Here’s the latest on Armstrong, for all Coinbase enthusiasts out there! NewLimit Raises $130M to Rewire Human Longevity Armstrong’s biotech venture NewLimit, co-founded with former GV partner Blake Byers and stem cell scientist Jacob Kimmel, just closed a $130 million Series B round. The startup, now valued at $810 million, is developing therapies that aim to restore youthful function to aging cells through epigenetic reprogramming. Early results are promising. The team has identified three prototype medicines targeting liver cells – improving their fat and alcohol processing capabilities in lab tests. While human trials are still years away, NewLimit is expanding into immune system research, with Armstrong citing the urgency of fighting what he calls the “largest source of human tragedy” – aging. The round was led by Kleiner Perkins and backed by a powerful lineup of investors including Founders Fund, Elad Gil, Patrick Collison, and Garry Tan. Say No to Aging: Tech Titans Are All In ! Armstrong isn’t alone in this mission. He joins the ranks of tech elites like Jeff Bezos, Larry Ellison, and Vitalik Buterin – all pouring hundreds of millions into anti-aging research. But Armstrong’s approach is distinctive: part-scientist, part-operator, and always ten steps ahead. Fighting for Stablecoin Regulations The Coinbase CEO hasn’t loosened his grip on crypto advocacy. Just yesterday on X, he called on the U.S. Senate to move forward on the GENIUS Act – a stablecoin regulation bill that could finally bring clear rules to the space. Congress has a real opportunity this week to advance stablecoin and market structure legislation. We strongly support the Senate starting debate on the GENIUS Act — and we need 60 votes to get there. We also welcome House efforts to build on FIT21’s momentum. Both chambers need… — Brian Armstrong (@brian_armstrong) May 6, 2025 The GENIUS Act would introduce a federal licensing regime, enforce reserve requirements for issuers, and create a dual regulatory model – splitting oversight between federal and state levels depending on issuer size. The push comes just as the Treasury predicts stablecoins could surge from $230B to $2T by 2028, presenting both an opportunity and a risk to traditional banking systems. Here’s how we see it: Brian Armstrong is betting on the future, and he’s doing it from all sides.

Most Read News

Moralis Money
Market Cap
24h Vol
64.41%
Bitcoin Share
0
Today News
Read the Disclaimer : All content provided herein our website, hyperlinked sites, associated applications, forums, blogs, social media accounts and other platforms (“Site”) is for your general information only, procured from third party sources. We make no warranties of any kind in relation to our content, including but not limited to accuracy and updatedness. No part of the content that we provide constitutes financial advice, legal advice or any other form of advice meant for your specific reliance for any purpose. Any use or reliance on our content is solely at your own risk and discretion. You should conduct your own research, review, analyse and verify our content before relying on them. Trading is a highly risky activity that can lead to major losses, please therefore consult your financial advisor before making any decision. No content on our Site is meant to be a solicitation or offer.